Business context and reporting period
The supplied filing is PerkinElmer, Inc.’s unaudited Form 10-Q for the quarter ended October 1, 2017, not a filing under the name Revvity, Inc. Verify the issuer and historical company-name mapping before relying on this summary. PerkinElmer reported two continuing segments: Discovery & Analytical Solutions and Diagnostics. Comparative periods ended October 2, 2016.
Financial performance and position
| Metric | Third quarter 2017 | Nine months 2017 |
|---|---|---|
| Revenue | $554.3 million, up 8% | $1,615.4 million, up 4% |
| Gross margin | 48.5%, up 19 basis points | 47.4%, down 18 basis points |
| Operating income from continuing operations | $79.8 million, versus $75.8 million | $207.4 million, versus $202.6 million |
| Income from continuing operations | $96.5 million; diluted EPS $0.87 | $195.3 million; diluted EPS $1.77 |
| Net income | $91.1 million; diluted EPS $0.82 | $333.8 million; diluted EPS $3.02 |
| Operating cash flow from continuing operations | Not provided separately for the quarter | $165.2 million, versus $181.2 million |
Nine-month total operating cash flow, including discontinued operations, was $160.4 million. Cash and cash equivalents were $709.5 million at October 1, 2017, compared with $359.3 million at January 1, 2017; current assets were $1.546 billion and current liabilities $597.5 million. Debt totaled approximately $1.111 billion, principally the 2021 and 2026 senior notes and financing lease obligations. The revolving facility had no borrowings and $988.6 million available; the separate $200 million term facility was also undrawn. The filing states the company was in compliance with applicable covenants.
Material changes versus prior period
- Q3 revenue growth came from both segments: Discovery & Analytical Solutions rose 6% to $385.4 million; Diagnostics rose 13% to $168.9 million. Nine-month segment revenue increased 2% and 9%, respectively.
- Continuing-operations operating income increased, but operating margin declined about 33 basis points in Q3, reflecting investment in product development, partly offset by productivity and cost-containment efforts.
- Nine-month net income included a $180.4 million pretax gain on the sale of Medical Imaging, completed May 1, 2017 for approximately $277.4 million. The sale contributed $138.4 million of after-tax discontinued-operation and disposition income for the nine-month period. Thus, reported net income growth is not a like-for-like measure of continuing performance.
- Q3 interest and other income was $25.2 million, substantially reflecting foreign-exchange gains on currency forwards tied to the planned EUROIMMUN acquisition. The nine-month period included $42.6 million of such gains.
- Cash from continuing operating activities fell $16.0 million year over year, with management citing cash outflows for accrued expenses and other items, as well as working-capital use including higher inventory.
Outlook, management commentary, risks and unusual items
No quantified revenue or earnings guidance is provided in the supplied text. Management expressed confidence in its positioning for growth in diagnostics and discovery markets, citing demand for OneSource laboratory services, environmental/food/industrial offerings, newborn and infectious-disease screening, and applied genomics. It also noted weakness in radioactive reagents and softer European academic demand.
PerkinElmer had agreed to acquire EUROIMMUN for up to 100% ownership; full participation would imply cash consideration of €1.2 billion, subject to customary conditions and regulatory approvals. The company had entered into currency forwards related to the proposed purchase and expected to use available cash, borrowing capacity and other financing as needed. Completion was not assured.
Other notable matters include $12.9 million of restructuring and contract-termination charges for the first nine months; management did not expect further charges for the specified plans, although residual lease payments may continue through 2022. The company reported $64.7 million of acquisition-related contingent consideration, with potential payments up to $83.0 million. It also disclosed $9.8 million of environmental remediation accruals and stated that ordinary-course legal matters were not expected to have a material adverse effect, while acknowledging uncertainty.
Key risks include foreign-exchange exposure (about 60% of business outside the U.S.), customer funding and order volatility, product-development and competitive risks, acquisition execution and integration, substantial debt and covenant constraints, potential impairment of goodwill/intangibles, regulatory compliance, and supply-chain or operational disruptions. Management stated disclosure controls were effective as of quarter-end. It expected to use tax attributes to limit cash taxes associated with the Medical Imaging sale and repatriation; approximately $1.3 billion of foreign earnings remained indefinitely reinvested.
Important facts for investors to verify
- Confirm the requested issuer identity: the filing names PerkinElmer, Inc.; establish how it relates to the requested Revvity, Inc. entity and which historical business is relevant.
- Separate continuing operating performance from Medical Imaging disposition gains and acquisition-hedge foreign-exchange gains when assessing earnings quality.
- Check the status, final consideration, financing, and subsequent outcome of the proposed EUROIMMUN acquisition; the filing’s €1.2 billion amount assumes 100% participation.
- Review the causes and sustainability of lower operating margins and operating cash flow, including R&D investment, inventory growth, and timing-related accrual payments.
- Assess debt maturities, covenant headroom, contingent-consideration outcomes, and the company’s ability to fund acquisitions, dividends, and other obligations.